Pelthos (PTHS) CFO awarded 33,472 RSUs with multi‑year vesting
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
Francis Knuettel II reported acquisition or exercise transactions in this Form 4 filing.
Pelthos Therapeutics Inc. reported that its CFO, Treasurer and Secretary, Francis Knuettel II, received a grant of 33,472 restricted stock units (RSUs), each representing one share of common stock under the company’s 2023 Equity Incentive Plan. The RSUs were granted as compensation for his service as an officer and may be settled solely in shares of common stock, subject to vesting.
The RSUs vest with one-third of the shares on July 2, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, contingent on continued service. The filing also shows indirect holdings of common stock by Camden Capital LLC (10,000 shares) and the Lara Knuettel Revocable Trust (12,816 shares); Knuettel may be deemed to beneficially own these shares but disclaims beneficial ownership except for his pecuniary interest. Share amounts reflect a 1-for-10 reverse stock split effective July 1, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Francis Knuettel II
Role
CFO, Treas & Secty
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 33,472 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 33,472 shares (Direct);
Common Stock — 10,000 shares (Indirect, By Camden Capital LLC)
Footnotes (1)
- Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I. The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
Key Figures
RSU grant size: 33,472 RSUs
Initial vesting date: July 2, 2026
Camden Capital LLC holdings: 10,000 shares
+3 more
6 metrics
RSU grant size
33,472 RSUs
Granted to CFO under 2023 Equity Incentive Plan
Initial vesting date
July 2, 2026
First one-third of RSUs vest
Camden Capital LLC holdings
10,000 shares
Indirect common stock holdings attributed to Camden Capital LLC
Lara Knuettel Trust holdings
12,816 shares
Indirect common stock holdings via Lara Knuettel Revocable Trust
Post-grant direct holdings
33,472 shares
Total common stock directly held following RSU settlement entry
Reverse stock split ratio
1-for-10
Effective July 1, 2025; all amounts adjusted accordingly
Key Terms
restricted stock units, 2023 Equity Incentive Plan, beneficially own, pecuniary interest, +1 more
5 terms
restricted stock units financial
"Represents shares of common stock ... issuable upon settlement of restricted stock units of the Issuer ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Equity Incentive Plan financial
"RSUs ... granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan"
beneficially own financial
"Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein"
reverse stock split financial
"Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
FAQ
What insider transaction did Pelthos Therapeutics (PTHS) report for Francis Knuettel II?
Pelthos Therapeutics reported a grant of 33,472 restricted stock units to CFO Francis Knuettel II. Each RSU represents one share of common stock, awarded as compensation under the 2023 Equity Incentive Plan and subject to multi-year vesting conditions tied to continued service.
How many RSUs did Pelthos Therapeutics (PTHS) grant to its CFO and what do they represent?
Pelthos granted 33,472 RSUs to its CFO, each equal to one share of common stock. The RSUs are payable solely in stock, issued under the 2023 Equity Incentive Plan, and give future share delivery rights rather than immediate cash or unrestricted stock.
What is the vesting schedule for the Pelthos (PTHS) RSUs granted to Francis Knuettel II?
The RSUs vest with the first one-third of shares on July 2, 2026. The remaining two-thirds vest in equal quarterly installments over the following two years, provided Knuettel continues serving the company on each scheduled vesting date.
How are Camden Capital LLC and the Lara Knuettel Revocable Trust involved in Pelthos (PTHS) holdings?
Camden Capital LLC holds 10,000 Pelthos shares and the Lara Knuettel Revocable Trust holds 12,816 shares. As manager and co‑trustee, Knuettel may be deemed a beneficial owner but formally disclaims beneficial ownership beyond his pecuniary interest in these entities.
Why did Pelthos Therapeutics (PTHS) file an amended Form 4 for this RSU grant?
The amendment moves the original RSU grant disclosure from Table II to Table I, aligning it with how the shares will be issued. It also reflects share amounts after Pelthos’s 1‑for‑10 reverse stock split effective July 1, 2025.